4 ms·
>The nasal version of the Oxford/AstraZeneca COVID vaccine failed to elicit an antibody response in an early trial, and the company is shelving its development.
by Markoff 4y ago
>The nasal version of the Oxford/AstraZeneca COVID vaccine failed to elicit an antibody response in an early trial, and the company is shelving its development.